To evaluate the evidence from randomised trials for the efficacy and safety of phytotherapeutic interventions in the management of biochemically recurrent (BCR) prostate cancer, indicated by prostate-specific antigen (PSA) progression, numbers progressing to/time to initiation of androgen-deprivation therapy or salvage therapy.
Introduction
Approximately 35% of men treated annually for localised prostate cancer with definitive local therapies, e.g. radical prostatectomy (RP), brachytherapy, and external beam radiation therapy (EBRT), will develop biochemical failure or biochemical recurrence (BCR) of disease [1] , detected by a rising serum PSA level within 10 years of treatment [2] . This usually signifies the presence of incurable disease, and can indicate disease progression years before clinical signs or symptoms develop [2] .
The small fraction (10-15%) of men with rapidly progressive BCR prostate cancer, signified by a PSA-doubling time (PSA-DT) of ≤3 months, have a high risk of clinical recurrence and cancer mortality. These are typically managed with early systemic therapy, usually in the form of androgen-deprivation therapy (ADT) initially [3] . For the remainder with more indolent PSA dynamics, however, there may be a period of several years of observation before embarking on salvage ADT [4] , with its associated toxicities [5] . Substantial anxiety during this period of watchful waiting (WW) [6] often drives patients to seek non-hormonal treatments. Complementary medicine use among men with prostate cancer ranges from 8% to 90% (median 31%) with 8% to 50% (median 30%) using it specifically for cancer care [7] . For herbal medicine use, the prevalence ranges from 1.2% to 24.5%. Evidence for the efficacy of non-hormonal herbal treatments (phytotherapies) is needed from studies in humans.
Scientific investigation of phytotherapeutic agents for potential benefit in prostate cancer chemoprevention is increasing, especially for green tea (Camelia sinensis) catechins, lycopene and soy (Glycine max) isoflavones, curcumin from turmeric (Curcuma longa), sulphoraphane and indole-3-carbinol from broccoli (Brassica oleracea). Preclinical studies and/or clinical trials also suggest benefits for resveratrol from grape skins or Japanese knotweed (Polygonum cuspidatum), pomegranate (Punica granatum) extract (POMx), Silymarin (from St Mary's/milk thistle, Silybum marianum), and mushrooms such as reishi (Ganoderma lucidum), turkey tail (Coriolus/Trametes), and shiitake (Lentinula edodes).
Potential anti-cancer mechanisms of these agents have been extensively reviewed elsewhere [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . These include inhibition of proliferation, induction of apoptosis, and cell cycle arrest. Soy isoflavones, indole-3-carbinol and 3,3 0 -diindolylmethane from broccoli, lycopene (predominantly found in tomatoes), (À)-epigallocatechin-3-gallate (green tea polyphenols), and curcumin from turmeric, are known to downregulate the signal transductions in androgen receptor (AR), protein kinase B (Akt), nuclear factor-jB (NF-jB), and other signal transduction pathways [18] . In vitro, sulphoraphane can inhibit cancer cells through a variety of mechanisms including inflammation, angiogenesis, and metastasis, and in vivo, its administration inhibited prostate cancer progression and metastasis in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice [11] . Pomegranate polyphenols modulate B-cell lymphoma 2 (Bcl-2) proteins, increase p21 and p27, and downregulate the cyclin-cyclin-dependent kinase (Cdk) complex network [12] . Silymarin (St Mary's/milk thistle) and its main active constituent, silibinin may enhance IGF-binding protein 3 (IGFBP-3) action and inhibit IGF-1-induced growth or affect levels of AR-regulating genes [10] . Mushroom polysaccharides stimulate T-cells, B-cells, neutrophils, and macrophage dependent immune system responses [16] . Systemic bioavailability is poor for curcumin and silibinin [10, 17] .
The objective of the present systematic review was to evaluate the evidence from randomised trials of phytotherapeutic interventions in the management of BCR prostate cancer for delaying disease progression, indicated by PSA progression, numbers progressing to/time to initiation of ADT or other salvage therapies.
Patients and Methods
The following electronic databases were searched (earliest to May 2015): EMBASE (Ovid), MEDLINE (Ovid), AMED (Ovid), Cochrane Central Register of Controlled Trials (CENTRAL) and CINAHL (EBSCO).
In addition, further relevant papers were identified using the 'related articles' function in PubMed, and by hand-searching reference lists of relevant journal articles and conference proceedings.
Search Strategy
Search strategy in MEDLINE, adapted for other databases. English language restriction was imposed.
Study Selection
Randomised clinical trials were eligible for inclusion in this review. Trials investigating phytotherapeutic extracts in combination with mainstream treatment were excluded.
Types of Participants
Patients with BCR hormone-sensitive prostate cancer after local therapy for histologically confirmed prostate cancer were included.
Types of Intervention
Trials investigating phytotherapeutic extracts, isolated phytochemicals, and plant-derived dietary components/items were included. Data from studies investigating herbal formulations containing additional vitamins or minerals were excluded. Studies of PC-SPES (mixture of eight different herbs, including chrysanthemum, liquorice and saw palmetto, plus the minerals selenium, calcium, magnesium, zinc and copper), which has been discredited due to adulteration with synthetic drugs, and of herbs administered via non-oral routes were excluded.
Types of Controls
Studies comparing interventions with inactive controls (e.g. placebo, no treatment, standard care or a waiting list control) or active control interventions (e.g. a different variant of the same intervention or a different herbal intervention) were included.
Types of Outcome Measures
The primary outcomes of the present review were 1 Disease progression denoted by changes in PSA levels and PSA kinetics (PSA velocity, i.e. rise rate; PSA-DT). 
Secondary Outcomes Included

Data Extraction and Methodological Quality Assessment
Two reviewers (D.v.D. and C.P. or K.B.) independently screened the titles and abstracts of all articles returned from the search strategy. When necessary, full-text articles were obtained to determine eligibility of the study. Any disagreement between the two authors was to be resolved by a third author (C.P. or K.B.). Data extraction from included studies was conducted by two investigators (D.v.D. and K.B.). Excluded studies were reviewed by D.v.D. and M.P.; discrepancies were checked by K.B.
The following data were extracted from the included articles: intervention, patient characteristics at baseline, trial design, sample size, duration, outcome measures, results, and AEs. Where necessary, authors were contacted for further details.
The quality of each study was assessed using the Cochrane Collaboration's risk of bias assessment tool [19] . Three reviewers (D.v.D., K.B. and C.P.) worked independently to determine selection, attrition, detection, performance, and reporting bias. Any discrepancies were resolved by discussion between the reviewers. To supplement the quality assessment, additional criteria were assessed according to the proposed elaboration of Consolidated Standards Of Reporting Trials (CONSORT) checklist item 4 for reporting randomised controlled trials (RCTs) of herbal medicines [20] .
Data Analysis
Lack of homogeneity across trials precluded any meaningful meta-analysis.
Results
Description of Studies
After the removal of duplicates, 318 articles were located and 23 full-text articles were assessed, five of which met the selection criteria (Fig. 1) . Key data extracted from the identified studies are included in Table 1 [11, [21] [22] [23] [24] . Of the five studies, two were placebo controlled [11, 22] , two compared the intervention with a different herbal intervention [23, 24] , and one was a variant of the same intervention (high-/low-dose) trial [21] . Study durations were as follows: 2 months [24] , three of 6 months [11, 22, 23] , and one study of up to 18 months [21] . However in the latter, only 58% completed either 18 months or met the protocoldefined progression.
Details of the 18 excluded studies are given in Table 2 [4, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] .
Patients
In all, 500 patients were randomised across these five studies, of which 489 were included in intention-to-treat analyses. Of these, 368 were patients with BCR prostate cancer. One placebo-controlled RCT was conducted in each of the UK [22] and France [11] ; the other three were conducted in the USA [21, 23, 24] .
One study (Pomi-T â ; Power Heath Products Ltd, Pocklington, York, UK) included men before and after radical therapies, on active surveillance (AS) or WW. The others included men after RP and/or radiotherapy (RT) for localised prostate cancer [11, 21, 23, 24] . One of these also included men on hormone therapy (LHRH analogue) [23] .
Four studies reported mean ages, which ranged from 69 to 75 years [11, 21, 23, 24] , and the other reported a median age of 75 years [23] . The mean baseline Gleason scores reported in two studies were 6.4 [22] and 6.45 [21] , respectively. The baseline PSA levels were specified in four studies: means of 0.76 ng/mL [11] , 6.5 ng/mL [22] , 5.3 ng/mL [21] , and a median value of 6.5 ng/mL [23] . The baseline PSA-DT was reported in three trials: means were 14.4 [11] and 14.7 months [21]; percentages of men with slow, moderate and fast PSA velocities were 38% (<4 months), 32% (4-9 months), and 30% (>9 months), respectively [24] .
The PSA inclusion criteria were specified in four studies: PSA level of >0.2 and <5 ng/mL after RP AE EBRT [11] ; no PSA level limits [24] ; a minimum PSA level of 10 ng/mL [23] ; a PSA level of ≥0.4 ng/mL after RP or multiple therapies, PSA level of >1.5 ng/mL after primary RT or cryotherapy; PSA nadir plus 2 ng/mL after EBRT with neoadjuvant hormonal therapy [21] .
Definitions of BCR were included in four studies: increasing PSA level at three successive measurements [11] ; at least two consecutive increases in serum PSA level [24] ; three successive elevations at a minimum interval of 2 weeks or at least two PSA values at least 2 weeks apart [23] ; rising PSA level at three or more time points at least a month apart, within the year before enrolment [21] .
PSA-DT calculations were reported in three of the studies [11, 21, 24] , and PSA velocity calculations described in a fourth (linear mixed-effects modelling with logarithm of PSA level [23] ). The PSA-DT was calculated either by fitting a simple linear regression model, using the slope, (the natural log of 2 divided by the slope obtained from fitting a linear regression of the natural log of PSA on time (months) [21] , consistent with the Memorial Sloan Kettering Cancer Centre calculation [11] ), or by using only the difference of the first and last PSA values (the natural log(2) 9 time interval/log final PSA À log initial PSA [24] ).
Current users of hormone therapy were included in one trial [24] . One study permitted LHRH analogue but no other hormones within the previous 4 weeks [23] . Three other studies included prior but not current users [11, 21, 22] . Two allowed hormone use in conjunction with RT [11, 22] and the other at least 1 year prior to enrolment [21] . There was no PSA-DT.
Male sex hormone levels Free PSA decreased during verum (P = 0.02).
Total PSA-DT unaffected, but NS increase from 9.5 months during placebo period to 10 months during verum.
In men in whom the free androgen index decreased (21/32), there was a significant decrease in the slopes of both total and free PSA (P = 0.04).
Male sex hormone levels lower with verum (P = 0.02): DHT, No Grade ≥III toxicities.
Bowel disturbances (one case obstipation and one diarrhoea in verum group) most frequently reported ALP, alkaline phosphatase; ALT, alanine aminotransferase; Apo, apolipoprotein AST, aspartate amino-transferase; CR, complete response; DHEA, dehydroepiandrosterone; DHT, dihydrotestosterone; GI, gastrointestinal; GT, c-glutamyltransferase; HT, hormone therapy; LDL, low-density lipoprotein; MCP, modified citrus pectin; PP, per protocol analysis; PR, partial response; QoL, quality of life; SM, Silybum marianum; TAG, trigylcerides.
significant difference across groups for current or prior use of hormone/anti-androgen therapy in any of the trials including these baseline data [11, 21, 23, 24] .
Interventions
Three types of interventions were identified in the studies: phytotherapeutic extracts, isolated phytochemicals, and plantderived dietary items. Interventions were delivered either as monotherapies or in combinations. Two studies investigated lycopene: dietary lycopene (tomatoes) >25 mg/day, calculated according to a food worksheet vs a powdered soy protein supplement 40 g/day (Solae Company, St. Louis, MO, USA; product Number AB20 Soy 1.2; each 40 g packet contained 24 mg genistein, 12 mg diadzein, and 2 mg glycitein. isoflavones were present in the aglycone form) for 1 month followed by the combination for a further month (both arms) [24] ; lycopene 30 mg/day (Lyc-o-mato â ,15 mg orally twice daily) vs a combination of lycopene at the same dose plus isoflavone capsules 80 mg daily (Solgen R 40 mg orally twice daily, LycoRed Company, Beer-Sheva, Israel) [23] . The other three studies investigated three different interventions: free stabilised sulphoraphane 60 mg daily (Nutrinov TM ) [11] ; Pomi-T, a combination of pomegranate (Punica granatum) extract, green tea (Camellia sinensis), broccoli sprouts (Brassica oleracea) and turmeric (Curcuma longa) -all 300 mg/day; and pomegranate (Punica granatum) extract 1 g or 3 g/day (POMx capsules, POM Wonderful LLC; 1 or 3 capsules/day, each containing 1 000 mg of polyphenol extract, comparable to %250 mL pomegranate juice, 90% polyphenols) [21] .
Controls/Comparators
Two studies were placebo-controlled trials (sulphoraphane [11] and Pomi-T [22] ) of 6 months duration; the pomegranate (POMx) study was a high-/low-dose study of up to 18 months duration [21] ; and the remaining two compared lycopene with a different phytotherapeutic agent (soy protein) for 2 months [24] /combination (lycopene plus soy isoflavones for up to 6 months) [23] .
Effects of Interventions
PSA levels
With all five interventions investigated, serum PSA levels either stabilised, decreased, or increased less than with placebo in a significant number of men on verum [the active study substance(s)]. PSA levels rose significantly less with sulphoraphane than with placebo over 6 months (P = 0.03), and the log PSA slope was significantly lower between baseline and the end of month 6 (P = 0.036), and particularly at months 3 and 6 (P = 0.011) [11] . In the Pomi-T study, the mean PSA level rose by 8.78% in the WW group on verum (95% CI À6.32 to 26.62), compared with an 80.34% (95% CI 50.54-116.55) rise in the placebo group (P = 0.001) [22] . The serum PSA level decreased in 25% of men administered tomato/lycopene for 1 month followed by a combination of tomato and soy protein for a further month, compared with 43% men administered soy protein for 1 month, followed by the combination for a further month, (36% men overall) [24] . No partial (50% PSA reduction) or complete (PSA level of ≤4 ng/mL) responses were seen with lycopene or lycopene plus soy isoflavones over 6 months [23] . However, 95% of patients in the lycopene group and 67% of the lycopeneisoflavones arm achieved stabilisation of serum PSA levels. Additionally, the PSA velocity significantly declined over the 6 months for both men with hormone-sensitive (P = 0.015) and hormone-refractory (P = 0.017) prostate cancer. Lycopene-only resulted in a significantly greater decline than the combination for the men with hormone-refractory disease (P = 0.021). In the pomegranate study (POMx), declining post-baseline PSA levels were seen in 13% (six patients in the low-dose arm and nine patients in the high-dose arm) and stable disease was seen in 36 (78%) patients in the low-dose arm and 40 (82%) in the high-dose arm [21] .
PSA-DT
All three studies reporting on PSA-DT found prolongation in a number of men [11, 21, 24] . An estimated 78% PSA-DT increase was seen with sulphoraphane (21.7 months) compared with placebo (12.2 months) [11] . The median PSA-DT extended from 14.26 to 28.9 months over 6 months. With tomato or soy protein for 1 month followed by a combination of the two for a further month, prolongation of the PSA-DT occurred in 58% of men, 65% in the tomato group, and 51% in the soy group [24] . The percentage of men whose PSA-DT was classified as slowest (>9 months) increased from 30% to 48% (P = 0.08), over the 2-month period. Administration of POMx capsules (1 or 3 g/day) resulted in a median lengthening of the PSA-DT from 11.9 to 18.5 months over the study period of up to 18 months (P < 0.001), with no significant difference between the dosage regimens [21] . In the 1g-POMx group, 76% of patients had a stable or lengthening PSA-DT and 46% had increases of ≥100% in PSA-DT. In the 3g-POMx group, 82% of patients had stable or lengthening PSA-DT, and 41% had ≥100% increase in PSA-DT.
Other
There was no significant effect on testosterone levels with sulphoraphane, POMx or lycopene and soy protein [11, 21, 24] . With administration of POMx capsules, oestradiol trended higher in the high-dose group from 28.0 to 32.3 pg/ mL, but not in the low-dose group. Sex hormone-binding globulin (SHBG) increased in both groups (42.5-54.7 endothelial growth factor (VEGF; P < 0.04) and total cholesterol, in both treatment arms [24] .
AEs
AEs were predominantly Grade I gastrointestinal events that were not significantly more frequent than with placebo in the RCTs. As shown in Table 1 , other events were minor in nature.
Risk of Bias
Risk of bias analysis was conducted in accordance with the Cochrane Collaboration guidelines for systematic reviews as an assessment of the validity of findings, and is summarised in Figure 2A ,B [11, [21] [22] [23] [24] . Most were categorised as low risk (60%) or unclear (20%). Random sequence generation was only described in two of the five studies. The two unblinded active-comparator studies were assessed as high risk on selection, performance, and detection bias criteria [23, 24] . In the sulphoraphane study, it would appear the trial product manufacturer had involvement in data analysis and interpretation [11] .
Reporting According to Elaboration of CONSORT for Trials of Herbal Interventions
All identified studies were assessed according to the elaborated CONSORT statement for trials of herbal interventions [20] . Generally compliance was low (Table 3 
Discussion
There is growing interest in researching phytotherapeutic interventions for BCR prostate cancer, especially ones that do not interfere with hormone receptors. Many men who experience PSA relapse after local treatment for prostate cancer turn to herbal and other complementary medicines in an attempt to delay the need for ADT, with its attendant side-effects, to prolong the time to metastases, and/or reduce prostate cancer-specific morbidity and mortality. We have presented the results of a systematic review of the evidence from randomised trials of phytotherapeutic extracts, isolated phytochemicals, and plant-derived dietary items in the context of BCR prostate cancer. To our knowledge, this is the first review of phytotherapeutic interventions in this cohort.
Of the 23 identified clinical studies, five met the criteria for inclusion. No two were identical in terms of intervention and comparator, thus precluding any meaningful meta-analysis. Overall, the quality of the studies was good, although generally sample sizes were small and durations short. Interventions investigated were sulphoraphane; lycopene vs soy (Glycine max) protein; lycopene with soy isoflavones; Pomi-T, which is a combination of pomegranate (Punica (b) (a) Fig. 2 Risk of bias summary (a) and graph (b) of included studies.
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© 2016 The Authors BJU International © 2016 BJU International granatum), green tea (Camellia sinensis), broccoli sprouts (Brassica oleracea) and turmeric (Curcuma longa); and pomegranate (Punica granatum) extract (POMx). Despite small sample sizes, all studies found serum PSA levels to stabilise, decrease, or rise more slowly in a significant number of men. Statistically significant results were found for a decrease in the mean PSA slope vs placebo with sulphoraphane, the mean PSA change with Pomi-T, and PSA velocity in both hormone-sensitive and hormone-refractory prostate cancer with lycopene and lycopene plus soy isoflavones. Prolongation of the PSA-DT was seen in all three studies reporting on this endpoint [11, 21, 24] , and reached statistical significance with sulphoraphane, and POMx. In the third, the 2-month study of tomato vs soy protein, it should be noted that PSA was not the main endpoint of interest, but rather metabolism and absorption [24] . Importantly, in the three studies that monitored testosterone levels across the treatment phase, no significant changes were found. With POMx [21], both dosage regimens resulted in non-significant increases in SHBG levels. Only one study measured changes in VEGF, which found significant reductions with both dietary lycopene and soy protein [24] . Safety and tolerability were very good for all interventions. However, these findings should be treated with caution pending replication of results from further adequately powered studies.
Limitations
Consistent with the findings of other reviews on phytotherapeutic interventions in prostate cancer [42] [43] [44] , Table 3 Reporting according to the proposed elaboration of CONSORT checklist Item 4 for reporting RCTs of herbal medicine. Cipolla et al. [11] Thomas et al. [22] Grainger et al. [24] Vaishampayan et al. [23] limitations include the number of studies identified, sample sizes, duration of follow-up, and lack of power in some studies to detect clinically meaningful changes in PSA or other biomarkers of disease progression. One study included men on both AS (before local therapy) and WW (after local therapy), without consistent reporting of sub-population analysis, thereby limiting our ability to determine the impact on the rising PSA population after local therapy [22] .
In addition, comparison of results across studies is hindered by the variety of ways used to report PSA endpoints: mean change in PSA/percentage change from baseline; percentage lower than control arm; percentage of men with a decrease in PSA; number of/percentage of men with a partial (>50% reduction) or complete PSA response; time to PSA progression. The PSA-DT was defined as the mean or median log slope; the number of men moving from one risk category (slow, moderate or fast) to another; the median or mean number of months' prolongation; and percentage change from baseline.
For adherence to the proposed elaboration of CONSORT checklist item 4 ( Table 3) for trials of herbal medicine, reporting was inadequate for information relating to the herb name, characteristics of the herbal product, quantitative description, and qualitative testing. A lack of complete and transparent reporting impacts on reproducibility of studies, as well as translation into clinical practice.
Abstracts published in proceedings of professional meetings were searched but not included in the review. As none of these was a negative study, this is unlikely to reflect publication bias. However, publication bias cannot be excluded. The key issues identified with phytotherapeutic research in this area are summarised in Table 4 .
The overall aim of the present review was to examine the evidence for phytotherapeutic interventions in prolonging metastasis-free survival in men with BCR prostate cancer. The attempt to pool or compare results from the identified studies highlighted several barriers to comparability of findings from phytotherapy research in this cohort; namely variations in study population, intervention, design and endpoints. As most studies do not concurrently measure other markers of tumour progression in participants, the possibility of the interventions masking PSA kinetics cannot be excluded.
Recommendations
Greater consensus among researchers designing clinical trials is needed to permit meta-analyses and meaningful comparisons of studies that would assist clinicians in advising patients of the risks and/or benefits of phytotherapeutic interventions in BCR prostate cancer. Four areas are candidates for such consensus:
1 Definitions of BCR, and the number and frequency of PSA readings over time: The authors propose that researchers use the AUA definition of BCR after RP (PSA level of >0.2 ng/mL measured 6-13 weeks after RP, followed by a confirmatory test showing a persistent PSA level of >0.2 ng/mL [45] . Researchers should also follow the AUA recommendation for defining BCR after RT by using the American Society for Radiation Oncology (ASTRO) definition of BCR (the midpoint between PSA nadir and the first of three consecutive rises in PSA level [5] ). 2 Stratification: Because metastasis-free survival is strongly influenced by the PSA-DT and Gleason score, it is important to stratify patients on these two factors (PSA-DT of <9 vs ≥9 months and Gleason score ≤3 + 4 vs ≥4 + 3 [2, 3] ). 3 Methods of calculating the PSA-DT: As recommended by the Prostate-Specific Antigen Working Group's Guidelines on PSA-DT, the calculation of PSA-DT is the natural log of 2 divided by the slope obtained from fitting a linear regression of the natural log of PSA on time (months) for at least three values of PSA all >0.2 ng/mL and all taken within 12 months [46] . 4 Reporting of results: Results should include, where available, change in the PSA-DT, 30% and/or 50% decline in PSA level and metastasis-free survival in accordance with the Prostate Cancer Working Group definitions [47] .
Endpoints
Although the PSA-DT is probably the most important prognostic factor in metastases-free survival and overall survival [2] , further evidence is needed to confirm findings that changes in PSA-DT after initiation of a therapy are prognostic for metastasis-free survival in patients with BCR disease [5, 48] . Inclusion of metastases-free survival as an endpoint is encouraged, despite necessitating lengthy followup periods. To determine whether effects endure, adequate follow-up periods, and non-treatment follow-up beyond the To ensure that interventions are not simply suppressing PSA, but also impacting on cancer progression, routine prostate imaging by CT and bone scans every 1-2 years, depending on PSA kinetics, is recommended.
Design
The importance of a placebo arm and adequate sample size to overcome the possibility of type II errors due to natural PSA variability is emphasised by the finding that calculated PSA-DT in BCR prostate cancer may naturally increase over time in the absence of therapy and may be influenced by the duration of PSA follow-up [49] .
Intervention
In 2006, an elaboration of CONSORT item 4 was proposed for reporting on clinical trials of herbal interventions [20] . As biologically defined agents, crude phytotherapeutic drugs vary in chemical composition according to agricultural practices and growing conditions. Other factors that determine whether different phytotherapeutic extracts achieve phyto-equivalence (the same therapeutic activity), include plant part used, extraction methods, solvents, ratio of crude herbal drug to solvent, presence or absence of standardisation, and the quantity of herbal product constituents per dosage unit form. Disclosure of this information is essential for researchers wishing to replicate studies, as well as for clinicians prescribing based on published findings to have confidence that they are using an equivalent agent/product. However, reporting according to this checklist remains poorly done [50] . Improved reporting according to the proposed elaboration of CONSORT item 4 for reporting on clinical trials of herbal interventions is therefore urgently required.
Conclusion
There is growing interest in finding safe and effective phytotherapeutic therapies that can delay time to metastases and reduce prostate cancer-specific mortality and morbidity in men with BCR after local treatment. High-quality studies in this area are lacking. Sulphoraphane, lycopene, soy isoflavones, POMx, and Pomi-T are safe and well-tolerated. There is limited evidence that they can affect PSA dynamics. No recommendation can be made for the use of these agents in managing prostate cancer morbidity and mortality until high-quality, fully powered, placebo-controlled studies are available.
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